Lipid nanoparticle for delivering nucleic acid drug, and preparation method therefor and use thereof
Through the three-component lipid nanoparticles assembled by steroid-cationic lipids and auxiliary lipids and polyethylene glycol lipids, the stability of nucleic acid drugs in an environment of 2 to 8°C is solved, and the efficient delivery of mRNA and Safety, suitable for a wide range of routes of administration.
Patent Information
- Application Number
- PCT/CN2024/090657
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-04-29
- Filing Date
- 2024-04-29
- Publication Date
- 2024-11-07
AI Technical Summary
There are stability problems in existing nucleic acid drug delivery systems in storage and transportation, especially mRNA-LNPs need to be preserved in ultra-low temperature environments. Many medical institutions lack this condition, which leads to difficulties in preservation and transportation of nucleic acid vaccines.
Steroid-cationic lipids, auxiliary lipids and polyethylene glycol lipids are used to assemble into three-component lipid nanoparticles to form a composition with good lyophilization stability, meeting the storage needs at 2 to 8°C.
It realizes efficient and stable delivery of mRNA, improves the adaptability of storage and transportation conditions of nucleic acid drugs, reduces storage costs, and causes higher specific antibody responses and better safety in experimental animals.
Smart Images

Figure CN2024090657_07112024_PF_FP_ABST
Abstract
Description
Lipid nanoparticles for delivering nucleic acid drugs, preparation method and use thereof Technical Field
[0001] The present invention belongs to the field of biomedicine, and specifically relates to a lipid nanoparticle for delivering nucleic acid drugs, and a preparation method and use thereof. Background Art
[0002] Nucleic acid drugs mainly refer to compounds containing nucleotide or deoxynucleotide structures with genetic characteristics and pharmacological activity. They can be used to treat tumors, tissue regeneration, wound healing, pulmonary fibrosis, inflammatory diseases, microbial infections, etc. After nucleic acid drugs are injected into the human body, an efficient and safe drug delivery system is required to deliver them to the lesion site. The drug delivery system needs to stay for a sufficient time to accurately target the lesion site while avoiding damage to normal cells.
[0003] At present, drug delivery systems can be divided into viral vectors and non-viral vectors. Viral vectors are less used in nucleic acid drugs due to their immunogenicity, tumorigenicity, and limited drug loading; non-viral vectors, such as polymers (polymer), lipids (liposome or LNP), can bind nucleic acid drugs to specific ligands so that they can target specific cells, and are more widely used in current nucleic acid drugs. LNP is one of the most widely used delivery systems in current nucleic acid drug research. The LNP delivery system can safely and effectively deliver nucleic acids. It has advantages such as high nucleic acid encapsulation rate, ability to effectively transfect cells, strong tissue penetrability, low cytotoxicity and immunogenicity, etc., which are conducive to the delivery of drugs. Compared with other drug delivery systems, it has huge advantages. Therefore, the LNP delivery system has broad development and application prospects.
[0004] In the prior art, LNP delivery systems are often made of ingredients such as ionizable lipids (cationic lipids), steroids, neutral lipids, polyethylene glycol lipids, and nucleic acid drugs. For example: Patent document AU2020325221A1 discloses a composition for delivering LNPs to target cells, comprising (i) ionizable lipids; (ii) sterols or other structured lipids; (iii) non-cationic auxiliary lipids or phospholipids; (iv) PEG lipids and (v) agents encapsulated in and / or associated with LNPs (such as nucleic acid molecules), and these four components enhance the delivery efficiency of target cells in a specific ratio; Patent document WO2021 / 250263A1 discloses a composition comprising ionizable lipids, phospholipids, sterols, polyethylene glycol lipids and one or more nucleic acids, and discloses a C14-PEG2000 lipid containing less than about 1 mol%, as well as a specific percentage of other lipids; Patent CN102712935B discloses a lipid particle comprising: cationic lipids; neutral lipids, zwitterionic lipids or anionic lipids; polyethylene glycol lipids; sterols and nucleic acids, and assembling the above components into a lipid particle with a solid core, wherein the solid core can achieve a higher coating efficiency; Patent document WO 2021 / 055849A1 discloses a lipid having the following structure: This structure can improve its safety, effectiveness and specificity; Patent document WO2021 / 026358Al discloses a target cell delivery lipid nanoparticle (LNP): including (i) ionizable lipids (ii) sterols or other structural lipids; (iii) non-cationic auxiliary lipids or phospholipids; (iv) payload; (v) polyethylene glycol lipids, as a drug delivery system, taking into account both safety and effectiveness. In recent years, it has been discovered that introducing cholesterol into ionizable lipid compounds can also be used to deliver nucleic acid drugs. Patent document US7514099B2 discloses a cholesterol amino lipid compound CLinDMA This compound can be combined with phospholipids, cholesterol, and polyethylene glycol lipids to form a four-component LNP or with phospholipids, DMOBA lipids, cholesterol, and PEG lipids to form a five-component LNP to deliver siRNA; Patent CN112424214A discloses an ionizable cationic lipid compound formed by cholesterol and linear olefins (3) This compound is combined with cholesterol, DPPC, DOPE and DMG-PEG200 to construct lipid nanoparticles for nucleic acid delivery. It requires five lipid excipients, is complex to construct, and has a poor polydispersity coefficient of -0.292 with a PDI. In order to adapt to different application scenarios, it is also particularly important to develop different delivery systems suitable for different routes of administration, such as using aerosol inhalation to treat lung-related diseases or prevent respiratory-related pathogen infections. At present, the stable storage of mRNA-LNP is still a major difficulty. Freeze-drying can achieve stable storage of mRNA-LNP at 2-8°C or even at room temperature. It can be seen that the existing technology optimizes the components in the composition and the cationic lipids. In order to further obtain a safer, more effective, stable, simple to construct LNP delivery system that can be applied to different routes of administration, it is also necessary to further develop its components and the structure of each component.
[0005] Traditional LNPs include four components: ionizable cationic lipids, amphiphilic phospholipids, pegylated lipids, and cholesterol. Due to the characteristics of mRNA itself, its storage and transportation using traditional LNPs must be carried out in an ultra-low temperature environment. According to current research, Pfizer's new crown mRNA vaccine can be stored for 6 months in an ultra-low temperature freezer at -70°C, and can be stored for 15 days in Pfizer's special insulated transport box with continuous addition of dry ice, while it can only be stored for 5 days in a normal hospital refrigerator at 2 to 8°C. Storage at extremely low temperatures of -70°C is common in research laboratories, but many medical centers do not have such equipment, and developing countries and economically underdeveloped areas lack such equipment. At present, there is no ready-made capacity in this field in China that can achieve -70°C conditions for transportation. Therefore, it is necessary to solve the problem of the preservation of nucleic acid vaccines.
[0006] Summary of the Invention
[0007] The present invention provides a lipid nanoparticle composition. Different from the traditional four-component LNP, the present invention covalently combines ionizable cationic lipids with steroids and then assembles them into lipid nanoparticles with auxiliary lipids and PEGylated lipids to form a three-component lipid nanoparticle composition. The lipid nanoparticle composition has good freeze-drying stability and can meet the requirements of storage at 2-8°C.
[0008] In a first aspect, the present invention provides a lipid nanoparticle composition for nucleic acid drug delivery, comprising: a steroid-cationic lipid compound, a helper lipid, and a polyethylene glycol lipid.
[0009] In one embodiment, the molar ratio of the steroid-cationic lipid:helper lipid:polyethylene glycol lipid is 30-80:20-80:0.5-20; preferably, the molar ratio of the steroid-cationic lipid:helper lipid:polyethylene glycol lipid is 30-80:30-80:0.5-20.
[0010] In one embodiment, the polyethylene glycol lipid is selected from 2[(polyethylene glycol)-2000]N,N-tetracosylacetamide (ALC-0159), 1,2-dimyristoyl-sn-glyceromethoxypolyethylene glycol (PEG-DMG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (PEG-DSPE), PEG-disterylglycerol (PEG-DSG), PEG-dipalmitoleyl, PEG-dioleyl, PEG-distearyl, PEG-diacylglyceramide (PEG-DAG), PEG-dipalmitoylphosphatidylethanolamine (PEG-DPPE) or PEG-1,2-dimyristoyloxypropyl-3-amine (PEG-c-DMA).
[0011] In one embodiment, the helper lipid is selected from a neutral lipid, a zwitterionic lipid or an anionic lipid; preferably, the helper lipid is selected from 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE), 2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DOPG), oleoylphosphatidylcholine (POPC), 1-palmitoyl-2-oleoylphosphatidylethanolamine (POPE), phosphorylcholine (DOPC), dimyristoylphosphatidylcholine (DMPC), phosphatidylcholine ( PLPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DAPC), phosphatidylethanolamine (PE), egg phosphatidylcholine (EPC), dilauroylphosphatidylcholine (DLPC), dimyristoylphosphatidylcholine (DMPC), 1-myristoyl-2-palmitoylphosphatidylcholine (MPPC), 1-palmitoyl-2-myristoylphosphatidylcholine (PMPC), 1-palmitoyl 1,2-diazanoyl-sn-glycero-3-phosphocholine (DBPC), 1-stearoyl-2-palmitoylphosphatidylcholine (SPPC), 1,2-eicosenoyl-sn-glycero-3-phosphocholine (DEPC), lysophosphatidylcholine, dilinoleoylphosphatidylcholine distearoylphosphatidylethanolamine (DSPE), or lysophosphatidylethanolamine.
[0012] In one embodiment, the composition further contains a nucleic acid drug; preferably, the nucleic acid drug is DNA or RNA; more preferably, the RNA is selected from antisense RNA, saRNA, mRNA, lncRNA, miRNA, siRNA, piRNA, gRNA, tsRNA, circRNA and self-replicating mRNA; more preferably, the nucleic acid drug is mRNA; more preferably, the composition is in the form of nucleic acid-lipid particles.
[0013] In one embodiment, the steroid-cationic lipid compound in the composition has the structure shown in formula (I):
[0014] wherein R1 is selected from -OR4, -NR4R5, -NR4C(=O)R5, -C(=O)OR5, -OC(=O)R5, -OC(=O)OR5, -CN, a nitrogen-containing heterocyclic group or a guanidine group;
[0015] Said R4 and R5 are independently selected from H, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkenyl or C 3-8 cycloalkynyl;
[0016] The G1 is selected from chemical bonds (-), C 1-9 Alkylene, C 2-9 Alkenylene, C 3-9 Alkynylidene, C 3-8 Cycloalkylene or C 3-8 cycloalkenylene;
[0017] Preferably, the number of consecutive carbon atoms in R1-G1- is no more than 10. For example, the number of consecutive carbon atoms in R1-G1- may be 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0018] G2 and G3 are each independently selected from a chemical bond (-), C 1-12 Alkylene, C 2-12 Alkenylene, C 2-12 Alkynylidene, C 3-12 Cycloalkylene, C 3-12 Cycloalkenylene, C 3-12 Cycloalkynylene or C 6-12 arylene;
[0019] L1 and L2 are each independently selected from a chemical bond (-), -O-, -S-, -O(C=O)O-, -(C=O)NR a -、-NR a (C=O)-, -O(C=O)-, -(C=O)O-, -SS-, -S(O) x -、-OS(O) x O-, -C(=O)S-, -SC(=O)-, -NR a C(=O)NR b -、-OC(=O)NR a -、-NR a C(=O)O-, -OC(=O)S-, -SC(=O)O-, -P(O)(OR a )O-、-OP(O)(OR a )O- or C 1-12 a combination of one or more of alkylene;
[0020] wherein x is selected from 0, 1 or 2;
[0021] Among them, R a 、R b Each independently selected from H, C1-12 Alkyl, C 2-12 Alkenyl or C 2-12 Alkynyl;
[0022] R2 is selected from naturally occurring or non-naturally occurring steroids;
[0023] R3 is selected from naturally occurring or non-naturally occurring steroids, C 6-24 Alkyl, C 6-24 Alkenyl, C 6-24 Alkynyl or C 6-24 Alkoxy.
[0024] In one embodiment, the R1 is selected from -OR4, -NR4R5, pyrazolyl, imidazolyl, piperazinyl, piperazinyl, piperidinyl, piperidinyl, guanidinyl, pyrrolyl or pyrrolidinyl; the R4 and R5 are each independently selected from H, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-8 Cycloalkyl or C 3-8 cycloalkenyl;
[0025] The G1 is a chemical bond (-), C 1-9 Alkylene, C 2-9 Alkenylene, C 3-8 Cycloalkylene or C 3-8 cycloalkenylene;
[0026] Preferably, the G1 is C 1-6 Alkylene or C 2-6 alkenylene;
[0027] The number of consecutive carbon atoms in R1-G1- does not exceed 10; specifically, the number of consecutive carbon atoms in R1-G1- can be 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
[0028] The G2 and G3 are each independently selected from a chemical bond (-), C 1-12 Alkylene, C 2-12 Alkenylene or C 2-12 Alkynylidene;
[0029] The L1 and L2 are each independently selected from -O(C=O)-, -(C=O)O-, -SS-, -O(C=O)O-, -NR a C(=O)O-, -(C=O)NR a -、-NR a (C=O)-, -C(=O)S-, -SC(=O)-, -OC(=O)NR a - or C 1-12 a combination of one or more of alkylene;
[0030] Among them, R a H, C 1-12 Alkyl, C 2-12 Alkenyl or C 2-12 Alkynyl;
[0031] In one embodiment, the R1 is selected from -OR4, -NR4R5, imidazolyl, piperazinyl or guanidinyl;
[0032] Said R4 and R5 are independently selected from H, -C 1-5 Alkyl;
[0033] The G1 is an unsubstituted C 1-6 alkylene;
[0034] The number of consecutive carbon atoms in R1-G1- does not exceed 10; specifically, the number of consecutive carbon atoms in R1-G1- can be 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
[0035] The G2 and G3 are each independently selected from a chemical bond (-) or C 1-10 alkylene;
[0036] The L1 and L2 are each independently selected from -O-, -O(C=O)-, -(C=O)O-, -(C=O)S-, -O(C=O)O-, -NHC(=O)O-, -NHC(=O)-,
[0037] In one embodiment, said R2 is a sterol;
[0038] Preferably, the sterol is an animal sterol, or an oxidized form or a reduced form thereof; and / or, the sterol is a plant sterol, or an oxidized form or a reduced form thereof; and / or, the sterol is a synthetic sterol, or an oxidized form or a reduced form thereof;
[0039] More preferably, the sterol is selected from cholesterol, an oxidized form of cholesterol, a reduced form of cholesterol, an alkyl lithocholate, stigmasterol, stigmasterol, campesterol, ergosterol or sitosterol;
[0040] More preferably, the sterol is an oxidized form of cholesterol, a reduced form of cholesterol, an alkyl lithocholate, stigmasterol, stigmasterol, campesterol, ergosterol or sitosterol;
[0041] More preferably, the sterol is selected from avenasterol, β-sitosterol, brassicasterol, ergocalciferol, campesterol, cholestanol, cholesterol, coprosterol, dehydrocholesterol, streptosterol, dihydroergocalciferol, dihydrocholesterol, dihydroergosterol, melanosterol, epicholesterol, ergosterol, fuccasterol, hexahydroluminosterol, hydroxycholesterol; lanosterol, luminosterol, alginosterol, sitostanol, sitosterol, stigmasterol, stigmasterol, cholic acid, glycocholic acid, taurocholic acid, deoxycholic acid or lithocholic acid;
[0042] More preferably, the structural formula of the sterol is as follows:
[0043] Where R is C 1-20 alkyl.
[0044] In one embodiment, the R3 is selected from the following structures:
[0045] Preferably, the R3 is selected from the following structures:
[0046] In one embodiment, the steroid-cationic lipid compound in the composition is selected from:
[0047] In one embodiment, the lipid nanoparticles have a nitrogen to phosphorus ratio of (1 to 15):1, including but not limited to 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1 or 15:1.
[0048] In one embodiment, the lipid nanoparticle has a diameter of 15 nm to 300 nm; preferably, the lipid nanoparticle has a diameter of 60 nm to 102 nm; more preferably, the lipid nanoparticle has a diameter of 80 nm to 90 nm.
[0049] In one embodiment, the dosage form of the lipid nanoparticle composition is a liquid preparation or a lyophilized powder.
[0050] In a second aspect, the present invention provides a method for preparing the lipid nanoparticles described herein, comprising dissolving the steroid-cationic lipid compound, neutral phospholipid and polyethylene glycol lipid described in the present invention in a solvent and mixing the mixture with a nucleic acid drug.
[0051] In one embodiment, the nucleic acid drug is mRNA.
[0052] In a third aspect, the present invention provides use of the lipid nanoparticle composition described herein in preparing a bioactive substance delivery system.
[0053] In one embodiment, the bioactive substance delivery system is an aerosol inhalation delivery system.
[0054] In one embodiment, the dosage form of the aerosol inhalation delivery system is a liquid preparation or a lyophilized powder.
[0055] In one embodiment, the aerosol inhalation delivery system is a liquid preparation aerosol administration, and / or nasal inhalation or oral inhalation; or the aerosol inhalation administration mode is mucosal administration, and the liquid preparation aerosol inhalation. Preferably, the aerosol inhalation administration mode is nasal inhalation or oral inhalation mucosal administration.
[0056] In one embodiment, the aerosol inhalation delivery system is a liquid formulation that can be administered by intramuscular injection.
[0057] In one embodiment, the delivery system further comprises a pharmaceutically acceptable excipient. Preferably, the excipient comprises one or more combinations of sodium acetate, tromethamine, potassium dihydrogen phosphate, sodium chloride, disodium hydrogen phosphate, and sucrose.
[0058] In one embodiment, the delivery system is a vaccine.
[0059] In one embodiment, the vaccine is a vaccine for preventing cancer, viral infection, bacterial infection or fungal infection; preferably, the virus is selected from: norovirus, Ebola virus, coronavirus, cytomegalovirus, dengue virus, Zika virus, coxsackievirus, enterovirus, hepatitis virus, herpes simplex virus, human papillomavirus, influenza virus, Marburg virus, measles virus, poliovirus, rabies virus, rotavirus or measles virus.
[0060] Beneficial effects of the present invention:
[0061] The lipid nanoparticle composition prepared using a steroid-cationic lipid compound exhibits excellent stability and transfection efficiency. These lipid nanoparticles can be used to deliver nucleic acid drugs, such as mRNA, to target cells or organs efficiently and stably. Furthermore, these LNPs can be used for aerosolized inhalation of mRNA. They can elicit high specific antibody responses in experimental animals and offer improved safety. BRIEF DESCRIPTION OF THE DRAWINGS
[0062] Figure 1 shows the expression of GFP-mRNA-LNP in Hep3B cells detected by fluorescence microscopy;
[0063] Figure 2 shows the ELISA test of serum antibody titers after mice were immunized with mRNA-LNP;
[0064] Figure 3a shows the CD8 T cell immunophenotype detected by ICS after mice were immunized with mRNA-LNPs;
[0065] Figure 3b shows the CD4 T cell immunophenotype detected by ICS after mice were immunized with mRNA-LNPs;
[0066] Figure 4 shows the expression of serum IL-6 in mice after high-dose administration of mRNA-LNP;
[0067] Figure 5 shows the DLS comparison of LNP before and after atomization;
[0068] FIG6 shows the expression of GFP fluorescent protein detected by fluorescence microscopy after GFP-mRNA-LNP was transfected into Hep3B cells before and after atomization;
[0069] Figure 7a shows images of the body and organs of mice after aerosol inhalation of Luc-mRNA-LNP;
[0070] Figure 7b shows the in vivo and organ imaging of mice after aerosol inhalation of Luc-mRNA-LNP. DETAILED DESCRIPTION
[0071] The technical solutions of the present invention will be described clearly and completely below in conjunction with the accompanying drawings of the present invention. Obviously, the embodiments described are only some embodiments of the present invention, not all. It should be noted that the methods used in the present invention are conventional methods unless otherwise specified, and the reagents used in the present invention are commercially available products unless otherwise specified. All other embodiments obtained by those of ordinary skill in the art based on the embodiments of the present invention without creative work are within the scope of protection of the present invention.
[0072] definition
[0073] As used in this specification, the following words and phrases are generally intended to have the meanings set forth below, unless the context in which they are used indicates otherwise.
[0074] As used herein, the term "lipid nanoparticle," "Lipid Nanoparticle," or "LNP" refers to a particle having a nanometer size, for example, 1 nm to 1,000 nm, which comprises one or more types of lipid molecules.
[0075] As used herein, the term "gene medicine" generally consists of a vector or delivery system containing an engineered gene construct, the active ingredient of which may be DNA, RNA, genetically modified viruses, bacteria or cells. By introducing exogenous genes into target cells or tissues, it replaces, compensates, blocks or corrects specific genes to achieve the purpose of treating and preventing diseases.
[0076] As used herein, the term "nucleic acid" refers to a polymer containing at least two deoxyribonucleotides or ribonucleotides in single- or double-stranded form, and includes DNA, RNA, and hybrids thereof.
[0077] As used herein, the term "lipid compound" or "lipid" refers to a group of organic compounds that include, but are not limited to, esters of fatty acids and are generally characterized by being poorly soluble in water but soluble in many organic solvents. Solvents of the present invention include, but are not limited to, water, benzene, toluene, pentane, hexane, methanol, ethanol, isopropanol, ether, ethyl acetate, acetone, and carbon tetrachloride. In some embodiments of the present invention, the solvent is ethanol.
[0078] As used herein, the term "alkyl" refers to a saturated straight or branched hydrocarbon group. 1-9 Alkyl groups include straight or branched chain alkyl groups containing 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, for example, but not limited to C 1- 8. C 2-7 、C 2-8 、C 3-6 or C 4-7 Alkyl; C 6-24 Alkyl groups include straight or branched chain alkyl groups containing 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 carbon atoms, including, but not limited to, C 6- 8. C 6-17 、C 6-22 、C 10-16 or C 14-17 Alkyl; C 1-5 Alkyl groups include straight or branched chain alkyl groups containing 1, 2, 3, 4 or 5 carbon atoms, including but not limited to C 1-4 、C 2-4 、C 2-3 、C 3-5 or C 4-5 Alkyl; C 1-20 Alkyl groups include straight or branched chain alkyl groups containing 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms, for example, but not limited to C 1-8 、C 1-10 、C 6-22、C 10-16 or C 14-17 alkyl.
[0079] As used herein, the term "alkenyl" refers to an unsaturated straight or branched hydrocarbon group containing one or more unsaturated carbon-carbon double bonds. The unsaturated carbon-carbon double bond may be present at any stable point along the chain. As used herein, C 2-9 Alkenyl includes straight or branched chain alkenyl groups containing 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, including but not limited to C 1-8 、C 2- 7. C 2-8 、C 3-6 or C 4-8 Straight-chain or branched alkenyl; C 6-24 Alkenyl includes straight or branched chain alkenyl groups containing 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 carbon atoms, for example, but not limited to C 6-8 、C 6-17 、C 6-22 、C 10-16 or C 14-17 Alkenyl.
[0080] As used herein, the term "alkynyl" refers to an unsaturated straight or branched chain hydrocarbon group containing one or more unsaturated carbon-carbon triple bonds. 2-9 Alkynyl groups include straight or branched chain alkynyl groups containing 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, including but not limited to C 1-8 、C 2-7 、C 2-8 、C 3-6 or C 4-7 Alkynyl.
[0081] As used herein, one or more carbon atoms in alkyl, alkenyl, and alkynyl groups other than the terminal positions may be substituted with heteroatoms such as nitrogen, oxygen, sulfur, and their oxides such as nitrogen oxides, carbonyl, and (oxy)sulfone groups, for example -(CH2) m -O-(CH2) n -、-(CH2) m -S-(CH2) n -、-(CH2) m -SS-(CH2) n -、-(CH2) m -CO-(CH2) n -、-(CH2) m -OCO-(CH2) n -、-(CH2) m -OCOO-(CH2)n -, (wherein m and n can be integers from 1 to 9) can be unsubstituted or substituted with one or more heteroatom substituents as described herein. In certain embodiments, the alkyl, alkenyl or alkynyl group does not include any heteroatoms.
[0082] As used herein, the term "alkylene" refers to a saturated divalent straight or branched hydrocarbon group. 1-9 Alkylene includes straight or branched chain alkylene containing 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, for example, but not limited to C 1-8 、C 2-7 、C 2-8 、C 3-6 or C 4-7 Alkylene; C 1-12 Alkylene includes straight or branched chain alkylene containing 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms, for example, but not limited to C 1-8 、C 2-7 、C 2-8 、C 3-6 or C 4-12 Alkylene; C 1-10 Alkylene includes straight or branched chain alkylene containing 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, for example, but not limited to C 1-8 、C 2-7 、C 2-8 、C 3-6 or C 4-10 Alkylene; C 1-6 Alkylene includes straight or branched chain alkylene containing 1, 2, 3, 4, 5 or 6 carbon atoms, for example, but not limited to C 1-5 、C 2-4 、C 3-6 or C 4-6 Alkylene.
[0083] As used herein, the term "alkenylene" refers to an unsaturated straight or branched chain hydrocarbon group containing one or more unsaturated carbon-carbon double bonds. 2-9 Alkenylene includes straight or branched chain alkenylene groups containing 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, for example, but not limited to C 2-7 、C 2-8 、C 3-6 or C 4-7 Alkenylene; C 2-12 The alkenylene group includes straight or branched chain alkenylene groups containing 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms, for example, but not limited to C 2-8 、C 2-7 、C3-6 or C 4-12 Alkenylene; C 2-6 Alkenylene includes straight or branched chain alkenylene groups containing 2, 3, 4, 5 or 6 carbon atoms, for example, but not limited to C 2-5 、C 2-4 、C 3-6 or C 4-6 Alkenylene.
[0084] As used herein, the term "alkynylene" refers to an unsaturated straight or branched chain hydrocarbon group containing one or more unsaturated carbon-carbon triple bonds. 2-12 Alkyne groups include straight or branched chain alkynylene groups containing 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms, including, but not limited to, C 2-8 、C 2-7 、C 3-6 or C 4-12 Alkynylidene; C 3-9 Alkyne groups include straight or branched chain alkynylene groups containing 3, 4, 5, 6, 7, 8, or 9 carbon atoms, including, but not limited to, C 3-6 、C 3- 8 or C 4-7 Alkynylidene.
[0085] As used herein, alkylene, alkenylene or alkynylene can comprise one or more cyclic aliphatic groups and / or one or more heteroatoms such as oxygen, nitrogen or sulphur, and can optionally be replaced by one or more substituents such as alkyl, halo, alkoxy, hydroxyl, amino, aryl, ether, ester or amide. Remove the end group position, one or more carbons at other positions can be replaced by heteroatoms such as nitrogen, oxygen, sulphur and oxides thereof such as nitrogen oxide, carbonyl, sulfone or sulfoxide. In certain embodiments, alkylene, alkenylene or alkynylene are unsubstituted. In certain embodiments, alkylene, alkenylene or alkynylene do not include any heteroatoms.
[0086] As used herein, the term "nitrogen-containing heterocyclic group" refers to a heterocyclic group containing a nitrogen atom in its structure, including but not limited to substituted or unsubstituted: aziridinyl, azetidinyl, β-propiolactam, pyrrolyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, caprolactam, pyranyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, piperazinyl, indolyl, benzimidazolyl, carbazolyl, quinolyl, isoquinolyl, pteridinyl, acridinyl, 7H-purinyl, phenazinyl, phenothiazinyl or 1H-aza base.
[0087] As used herein, the term "alkoxy" refers to an "alkyl-O-" group, wherein alkyl is as defined herein. As used herein, C 6-24Alkoxy includes straight or branched chain alkoxy containing 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 carbon atoms, for example, but not limited to C 6-8 、C 6-17 、C 6-22 、C 10-16 or C 14-17 Alkoxy.
[0088] As used herein, the term "cycloalkyl" refers to a saturated cyclic hydrocarbon group. 3-8 Cycloalkyl groups include cycloalkyl groups containing 3, 4, 5, 6, 7 or 8 carbon atoms, for example, but not limited to C 3-7 、C 4-7 or C 3-6 Cycloalkyl.
[0089] As used herein, the term "cycloalkenyl" refers to a cyclic hydrocarbon group containing at least one carbon-carbon double bond. 3-8 Cycloalkenyl groups include cycloalkenyl groups containing 3, 4, 5, 6, 7 or 8 carbon atoms, including but not limited to C 3-7 、C 4- 7 or C 3-6 Cycloalkenyl.
[0090] As used herein, the term "cycloalkynyl" refers to a cyclic hydrocarbon group containing at least one carbon-carbon triple bond. 3-8 Cycloalkynyl groups include cycloalkynyl groups containing 3, 4, 5, 6, 7 or 8 carbon atoms, including but not limited to C 3-7 、C 4-7 or C 3-6 Cycloalkynyl.
[0091] As used herein, the term "cycloalkylene" refers to a divalent cycloalkyl group that is used to link two structures together. 3-12 Cycloalkylene includes cycloalkylene groups containing 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms, including but not limited to C 3-8 、C 4-7 、C 5-8 or C 6-12 Cycloalkylene; C 3-8 Cycloalkylene includes cycloalkyl groups containing 3, 4, 5, 6, 7 or 8 carbon atoms, including but not limited to C 3-7 、C 4-7 or C 6-8 Cycloalkylene.
[0092] As used herein, the term "cycloalkenylene" refers to a divalent cycloalkenyl group that is used to link two structures together. 3-12 Cycloalkenylene groups include cycloalkenylene groups containing 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms, including but not limited to C 3-8 、C 4-7 、C 5-8 or C 6-12 Cycloalkenylene; C 3-8 Cycloalkenylene includes cycloalkenylene containing 3, 4, 5, 6, 7 or 8 carbon atoms, for example, including but not limited to C 3-7 、C 4-7 or C 6-8 Cycloalkenylene.
[0093] As used herein, the term "cycloalkynylene" refers to a divalent cycloalkynyl group that is used to link two structures together. 3-12 Cycloalkynylene groups include cycloalkynylene groups containing 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms, including but not limited to C 3-8 、C 4-7 、C 5-8 or C 6-12 Cycloalkynylene; C 3-8 Cycloalkynylene groups include cycloalkynylene groups containing 3, 4, 5, 6, 7 or 8 carbon atoms, for example, including but not limited to C 3-7 、C 4-7 or C 6-8 Cycloalkynylene.
[0094] As used herein, the term "arylene" refers to a divalent aromatic group that is used to link two structures together, wherein aryl includes monocyclic aromatic groups (having, for example, 4n+2 delocalized electrons) and polycyclic aromatic groups. As used herein, C 6- 12 Arylene groups include those containing 6, 7, 8, 9, 10, 11 or 12 carbon atoms, including but not limited to C 6-8 、C 6- 9. C 6-12 Arylene.
[0095] As used herein, the term "cationic lipid" refers to a lipid molecule that is capable of becoming positively charged in response to environmental pH or hydrogen ion activity.
[0096] As used herein, the term "helper lipid" refers to a lipid that is not positively charged under ambient pH conditions, including neutral lipids that are not charged, zwitterionic lipids, and negatively charged anionic lipids.
[0097] As used herein, the term "PEGylated lipid" refers to a lipid molecule comprising a lipid portion and a polyethylene glycol portion.
[0098] As used herein, the term "delivery system" refers to a formulation or composition that regulates the spatial, temporal, and dosage distribution of a biologically active ingredient in an organism.
[0099] Example
[0100] Example 1 Synthesis of Compound 1
[0101] Step 1: Synthesis of 6-bromohexyl 2-hexyldecanoate (1a)
[0102] 2-Hexyldecanoic acid (2.12 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and 6-bromohexanol (0.93 g, 5.0 mmol), 4-dimethylaminopyridine (DMAP, 0.21 g, 2.0 mmol), and triethylamine (0.62 g, 6.0 mmol) were added and stirred to dissolve. A dichloromethane solution of EDC.HCL (1.10 g, 6.0 mmol) was added dropwise. After the addition was complete, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3, and the mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 1a (1.45 g, light yellow oil) with a yield of 70%.
[0103] MS m / z(ESI):419.2[M+1]
[0104] Step 2: Synthesis of 6-((4-hydroxybutyl)amino)hexyl 2-hexyldecanoate (1b)
[0105] At room temperature, 6-bromohexyl 2-hexyldecanoate 1a (1.28 g, 3 mmol) was dissolved in 20 mL of ethanol, and 4-amino-1-butanol (4.00 g, 45 mmol) was added. The temperature was raised to 50°C and stirred for 8 h. The reaction progress was monitored. After the raw materials were completely consumed, the temperature was lowered to room temperature. The ethanol was removed at 45°C, and the crude product was dissolved in dichloromethane and washed three times with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 1b (1.13 g, light yellow oil).
[0106] MS m / z(ESI):428.4[M+1]
[0107] Step 3: Synthesis of 6-bromohexyl cholesteryl carbonate (1c)
[0108] 6-Bromohexanol (0.91 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and 4-dimethylaminopyridine (1.22 g, 10 mmol) was added. Then, p-nitrophenyl chloroformate (1.11 g, 5.5 mmol) was added in batches. The reaction was stirred at room temperature for 3 h. Cholesterol (2.16 g, 5.6 mmol) was added to the reaction solution, and the mixture was stirred at room temperature overnight. After TLC showed that the reaction was complete, 20 mL of dichloromethane was added to dilute the mixture, and the mixture was washed with 30 mL of saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain product 1c (1.83 g, light yellow oil) with a yield of 62%.
[0109] MS m / z(ESI):593.3[M+1]
[0110] Step 4: Synthesis of compound 1
[0111] 6-((4-Hydroxybutyl)amino)hexyl 2-hexyldecanoate 1b (428 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, 6-bromohexyl cholesteryl carbonate 1c (711 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 1 (470 mg, light yellow oil) in a 50% yield.
[0112] MS m / z(ESI):941.4[M+1]
[0113] 1H NMR (300MHz, CDCl3): δ5.40 (t, 1H, J = 5.4Hz), 4.53-4.40 (m, 1H), 4.20-4.02 (m, 4H), 3.67- 3.61(m,2H),3.58-3.50(m,2H),2.47-2.42(m,8H),2.03-1.72(m,5H),1.67-0.85(m,82H), 0.70(s,3H)
[0114] Example 2 Synthesis of Compound 2
[0115] 6-Bromohexyl cholesteryl carbonate 1c (1.48 g, 2.5 mmol) was dissolved in tetrahydrofuran, and acetonitrile, 4-amino-1-butanol (89.2 mg, 1.0 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 2 (679 mg, light yellow solid) in a 61% yield.
[0116] MS m / z(ESI):1115.2[M+1]
[0117] 1H NMR (300MHz, CDCl3): δ5.40(t,2H,J=5.4Hz), 4.53-4.40(m,2H), 4.15(t,4H,J=5.6Hz), 3.76(t,2H,J=5.4Hz), 3.20-3.01(m,6H),2.45-2.31(m,4H),2.02-1.75(m,16H),1.74-1.22(m,36H),1.19-0.87(m,44H),0.70(s,6H)
[0118] Example 3 Synthesis of Compound 3
[0119] Step 1: Synthesis of 6-((2-(dimethylamino)ethyl)amino)hexyl 2-hexyldecanoate (3a)
[0120] At room temperature, 6-bromohexyl 2-hexyldecanoate 1a (1.28 g, 3 mmol) was dissolved in 20 mL of ethanol, and N,N-dimethylethylenediamine (4.00 g, 45 mmol) was added. The temperature was raised to 50°C and stirred for 8 h. The reaction progress was monitored. After the raw materials were completely consumed, the temperature was lowered to room temperature. The ethanol was removed at 45°C, and the crude product was dissolved in dichloromethane and washed three times with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated to obtain compound 3a (1.20 g, light yellow oil).
[0121] MS m / z(ESI):427.4[M+1]
[0122] Step 2: Synthesis of compound 3
[0123] 6-((2-(Dimethylamino)ethyl)amino)hexyl 2-hexyldecanoate 3a (426 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, 6-bromohexyl cholesteryl carbonate 1c (711 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 3 (517 mg, light yellow oil) in a 55% yield.
[0124] MS m / z(ESI):940.0[M+1]
[0125] 1H NMR (300MHz, CDCl3): δ5.40(t,1H,J=5.4Hz),4.53-4.40(m,1H),4.20-4.02(m,3H),3.76-3.61( m,2H),3.45-3.38(m,3H),2.94-2.85(m,1H),2.55-2.27(m,5H),2.03-0.85(m,70H),0.70(s,3H)
[0126] Example 4 Synthesis of Compound 4
[0127] Step 1: Synthesis of 6-((2-hydroxyethyl)amino)hexyl 2-hexyldecanoate (4a)
[0128] At room temperature, 6-bromohexyl 2-hexyldecanoate 1a (1.28 g, 3 mmol) was dissolved in 20 mL of ethanol, and ethanolamine (2.75 g, 45 mmol) was added. The temperature was raised to 50°C and stirred for 8 h. The reaction progress was monitored. After the starting material was completely consumed, the temperature was lowered to room temperature. The ethanol was removed at 45°C, and the crude product was dissolved in dichloromethane and washed three times with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 4a (1.01 g, light yellow oil).
[0129] MS m / z(ESI):400.4[M+1]
[0130] Step 2: Synthesis of compound 4
[0131] 6-((2-Hydroxyethyl)amino)hexyl 2-hexyldecanoate 4a (400 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, 6-bromohexyl cholesteryl carbonate 1c (711 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 4 (474 mg, light yellow oil) in a 52% yield.
[0132] MS m / z(ESI):913.1[M+1]
[0133] 1H NMR (300MHz, CDCl3): δ5.40(t,1H,J=5.4Hz),4.53-4.40(m,1H),4.20-4.02(m,4H),3.67-3.61( m,2H),3.58-3.50(m,4H),2.47-2.42(m,2H),2.03-1.72(m,5H),1.67-0.85(m,82H),0.70(s,3H)
[0134] Example 5 Synthesis of Compound 5
[0135] Step 1: Synthesis of 2-hexyldecyl 8-bromooctanoate (5a)
[0136] 8-Bromooctanoic acid (1.12 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and 2-hexyldecanol (1.21 g, 5.0 mmol), DMAP (0.21 g, 2.0 mmol), and triethylamine (0.62 g, 6.0 mmol) were added and stirred to dissolve. A solution of EDC.HCl (1.10 g, 6.0 mmol) in dichloromethane was added dropwise. After completion of the addition, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3, and the mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 5a (1.52 g, light yellow oil) in a yield of 68%.
[0137] MS m / z(ESI):447.2[M+1]
[0138] Step 2: Synthesis of 2-hexyldecyl 8-((4-hydroxybutyl)amino)octanoate (5b)
[0139] At room temperature, 2-hexyldecyl 8-bromooctanoate 5a (1.34 g, 3 mmol) was dissolved in 20 mL of ethanol, butanolamine (4.00 g, 45 mmol) was added, and the temperature was raised to 50°C and stirred for 8 h. The reaction progress was monitored. After the starting material was completely consumed, the temperature was lowered to room temperature. The ethanol was removed at 45°C, and the crude product was dissolved in dichloromethane and washed three times with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 5b (1.21 g, light yellow oil).
[0140] MS m / z(ESI):456.4[M+1]
[0141] Step 3: Synthesis of 8-bromooctanoic acid cholesterol ester (5c)
[0142] 8-Bromooctanoic acid (1.12 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane. Cholesterol (1.93 g, 5.0 mmol), DMAP (0.21 g, 2.0 mmol), and triethylamine (0.62 g, 6.0 mmol) were added and stirred to dissolve. A dichloromethane solution of EDC-HCl (1.10 g, 6.0 mmol) was added dropwise. After completion of the addition, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3. The mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to afford compound 5c (1.77 g, light yellow oil) in a 60% yield.
[0143] MS m / z(ESI):591.4[M+1]
[0144] Step 4: Synthesis of compound 5
[0145] 2-Hexyldecyl 8-((4-hydroxybutyl)amino)octanoate 5b (455 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, cholesteryl 8-bromooctanoate 5c (708 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 5 (464 mg, light yellow oil) in a 48% yield.
[0146] MS m / z(ESI):967.6[M+1]
[0147] 1H NMR (300MHz, CDCl3): δ5.40 (t, 1H, J = 5.4Hz), 4.53-4.40 (m, 1H), 4.20-4.02 (m, 2H), 3.67 -3.61(m,2H),2.64(t,6H,J=5.4Hz),2.37-2.25(m,6H),2.10-0.85(m,93H),0.70(s,3H)
[0148] Example 6 Synthesis of Compound 6
[0149] Step 1: Synthesis of 6-((3-(1H-imidazol-1-yl)propyl)amino)hexyl 2-hexyldecanoate (6a)
[0150] At room temperature, 6-bromohexyl 2-hexyldecanoate 1a (1.28 g, 3 mmol) was dissolved in 20 mL of ethanol, and 1-(3-aminopropyl)imidazole (5.63 g, 45 mmol) was added. The temperature was raised to 50°C and stirred for 8 h. The reaction progress was monitored. After the starting material was completely consumed, the temperature was lowered to room temperature. The ethanol was removed at 45°C, and the crude product was dissolved in dichloromethane and washed three times with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 6a (1.46 g, light yellow oil).
[0151] MS m / z(ESI):464.4[M+1]
[0152] Step 2: Synthesis of compound 6
[0153] 6-((3-(1H-imidazol-1-yl)propyl)amino)hexyl 2-hexyldecanoate 6a (463 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, 6-bromohexyl cholesteryl carbonate 1c (711 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 6 (517 mg, light yellow oil) in a 53% yield.
[0154] MS m / z(ESI):976.9[M+1]
[0155] 1H NMR (300MHz, CDCl3): δ7.49 (s, 1H), 7.08 (d, 1H, J = 5.6Hz), 6.93 (d, 1H, J = 5.6Hz), 5.40 (t, 1H, J = 5 .4Hz),4.53-4.40(m,1H),4.20-3.95(m,5H),2.47-2.30(m,9H),2.36-0.85(m,87H),0.70(s,3H)
[0156] Example 7 Synthesis of Compound 7
[0157] Step 1: Synthesis of 6-bromohexylundecylcarbamate (7a)
[0158] 6-Bromohexanol (0.91 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and 4-dimethylaminopyridine (1.22 g, 10 mmol) was added. Then, p-nitrophenyl chloroformate (1.11 g, 5.5 mmol) was added in batches, and the reaction was stirred at room temperature for 3 h. Undecylamine (0.96 g, 5.6 mmol) was added to the reaction solution, and the mixture was stirred at room temperature overnight. After TLC showed that the reaction was complete, 20 mL of dichloromethane was added to dilute the mixture, and the mixture was washed with 30 mL of saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to obtain compound 7a (1.23 g, light yellow oil) with a yield of 65%.
[0159] MS m / z(ESI):378.2[M+1]
[0160] Step 2: Synthesis of 6-((4-hydroxybutyl)amino)undecylcarbamate (7b)
[0161] At room temperature, 6-bromohexylundecylcarbamate 7a (1.13 g, 3 mmol) was dissolved in 20 mL of ethanol, butanolamine (4.00 g, 45 mmol) was added, and the temperature was raised to 50°C and stirred for 8 h. The reaction progress was monitored. After the starting material was completely consumed, the temperature was lowered to room temperature. The ethanol was removed at 45°C, and the crude product was dissolved in dichloromethane and washed three times with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 7b (1.14 g, light yellow oil).
[0162] MS m / z(ESI):387.4[M+1]
[0163] Step 3: Synthesis of compound 7
[0164] 6-((4-Hydroxybutyl)amino)undecylcarbamic acid hexyl ester 7b (386 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, 6-bromohexyl cholesteryl carbonate 1c (711 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 7 (459 mg, light yellow oil) in a 51% yield.
[0165] MS m / z(ESI):900.4[M+1]
[0166] 1H NMR (300MHz, CDCl3): δ5.42(t,1H,J=5.4Hz),4.80-4.71(m,1H),4.51-4.40(m,1H),4.20-4.02(m,4H),3. 75-3.61(m,2H),3.20-3.11(m,2H),2.91-2.73(m,5H),2.43-2.36(m,2H),2.10-0.83(m,79H),0.70(s,3H)
[0167] Example 8 Synthesis of Compound 8
[0168] Step 1: Synthesis of S-undecyl 8-bromooctane sulfate (8a)
[0169] 8-Bromooctanoic acid (1.12 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and undecanethiol (0.94 g, 5.0 mmol), DMAP (0.21 g, 2.0 mmol), and triethylamine (0.62 g, 6.0 mmol) were added and stirred to dissolve. A solution of EDC-HCl (1.10 g, 6.0 mmol) in dichloromethane was added dropwise. After completion of the addition, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3, and the mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 8a (1.30 g, light yellow oil) in a 66% yield.
[0170] MS m / z(ESI):393.2[M+1]
[0171] Step 2: Synthesis of S-undecyl 8-((4-hydroxybutyl)amino)octylthioate (8b)
[0172] At room temperature, S-undecyl 8-bromooctane sulfate 8a (1.18 g, 3 mmol) was dissolved in 20 mL of ethanol, butanolamine (4.00 g, 45 mmol) was added, and the temperature was raised to 50 ° C. and stirred for 8 h. The reaction progress was monitored. After the starting material was completely consumed, the temperature was lowered to room temperature. The ethanol was removed at 45 ° C. The crude product was dissolved in dichloromethane and washed three times with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 8b (1.18 g, light yellow oil).
[0173] MS m / z(ESI):402.3[M+1]
[0174] Step 3: Synthesis of compound 8
[0175] S-Undecyl 8-((4-hydroxybutyl)amino)octanethioate 8b (401 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, 6-bromohexyl cholesteryl carbonate 1c (711 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 8 (458 mg, light yellow oil) in a 50% yield.
[0176] MS m / z(ESI):914.9[M+1]
[0177] 1H NMR (300MHz, CDCl3): δ5.42 (t, 1H, J = 5.4Hz), 4.51-4.40 (m, 1H), 4.20-4.02 (m, 2H), 3.6 5-3.51(m,2H),2.91-2.83(m,2H),2.60-2.36(m,10H),2.10-0.86(m,82H),0.70(s,3H)
[0178] Example 9 Synthesis of Compound 9
[0179] Step 1: Synthesis of 6-((4-((tert-Butoxycarbonyl)amino)butyl)amino)hexyl 2-hexyldecanoate (9a)
[0180] At room temperature, 6-bromohexyl 2-hexyldecanoate 1a (1.28 g, 3 mmol) was dissolved in 20 mL of ethanol, and BOC-1,4-butanediamine hydrochloride (10.1 g, 45 mmol) was added. The temperature was raised to 50°C and stirred for 8 h. The reaction progress was monitored. After the raw materials were completely consumed, the temperature was lowered to room temperature. The ethanol was removed at 45°C, and the crude product was dissolved in dichloromethane and washed three times with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 9a (1.51 g, light yellow oil).
[0181] MS m / z(ESI):527.5[M+1]
[0182] Step 2: Synthesis of compound 9b
[0183] 6-((4-((tert-Butoxycarbonyl)amino)butyl)amino)hexyl 2-hexyldecanoate 9a (526 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, 6-bromohexyl cholesteryl carbonate 1c (711 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 9b (540 mg, light yellow oil) in a 52% yield.
[0184] MS m / z(ESI):1039.9[M+1]
[0185] Step 3: Synthesis of compound 9
[0186] Compound 9b (1.04 g, 1.0 mmol) was dissolved in dichloromethane. A solution of trifluoroacetic acid in dichloromethane was added under ice-cooling, and the mixture was stirred at room temperature for 16 h. The trifluoroacetic acid was removed by rotary evaporation, and the mixture was dissolved in dichloromethane. The mixture was washed twice with saturated sodium bicarbonate solution. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 9 (460 mg, light yellow oil) in a 49% yield.
[0187] MS m / z(ESI):940.1[M+1]
[0188] 1H NMR (300MHz, CDCl3): δ5.40 (t, 1H, J = 5.4Hz), 4.63-4.40 (m, 1H), 4.19-4.03 (m ,4H),2.79-2.70(m,2H),2.55-2.28(m,10H),2.02-0.87(m,89H),0.70(s,3H)
[0189] Example 10 Synthesis of Compound 10
[0190] Step 1: Synthesis of 4-bromobutyl cholesteryl carbonate (10a)
[0191] 4-Bromobutanol (0.77 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and 4-dimethylaminopyridine (1.22 g, 10 mmol) was added. Then, p-nitrophenyl chloroformate (1.11 g, 5.5 mmol) was added in batches. The reaction was stirred at room temperature for 3 h. Cholesterol (2.16 g, 5.6 mmol) was added to the reaction solution, and the mixture was stirred at room temperature overnight. After TLC showed that the reaction was complete, 20 mL of dichloromethane was added to dilute the mixture, and the mixture was washed with 30 mL of saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain product 10a (1.50 g, light yellow oil) in a yield of 53%.
[0192] MS m / z(ESI):565.3[M+1]
[0193] Step 2: Synthesis of compound 10
[0194] 6-((3-(1H-imidazol-1-yl)propyl)amino)hexyl 2-hexyldecanoate 6a (463 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, 4-bromobutyl cholesteryl carbonate 10a (678 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 10 (455 mg, light yellow oil) in a 48% yield.
[0195] MS m / z(ESI):948.9[M+1]
[0196] 1H NMR (300MHz, CDCl3): δ7.49 (s, 1H), 7.08 (d, 1H, J = 5.6Hz), 6.93 (d, 1H, J = 5.6Hz), 5.40 (t, 1H, J = 5 .4Hz),4.53-4.40(m,1H),4.20-3.95(m,6H),2.47-2.30(m,8H),2.36-0.85(m,83H),0.70(s,3H)
[0197] Example 11 Synthesis of Compound 11
[0198] Step 1: Synthesis of 2-bromoethyl cholesteryl carbonate (11a)
[0199] 2-Bromoethanol (0.63 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and 4-dimethylaminopyridine (1.22 g, 10 mmol) was added. Then, p-nitrophenyl chloroformate (1.11 g, 5.5 mmol) was added in batches, and the reaction was stirred at room temperature for 3 h. Cholesterol (2.16 g, 5.6 mmol) was added to the reaction solution, and the mixture was stirred at room temperature overnight. After TLC showed that the reaction was complete, 20 mL of dichloromethane was added to dilute the mixture, and the mixture was washed with 30 mL of saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to obtain product 11a (1.53 g, light yellow oil) with a yield of 57%.
[0200] MS m / z(ESI):537.3[M+1]
[0201] Step 2: Synthesis of compound 11
[0202] 6-((3-(1H-imidazol-1-yl)propyl)amino)hexyl 2-hexyldecanoate 6a (463 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, 2-bromoethyl cholesteryl carbonate 11a (644 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 11 (506 mg, light yellow oil) in a yield of 55%.
[0203] MS m / z(ESI):920.8[M+1]
[0204] 1H NMR (300MHz, CDCl3): δ7.49 (s, 1H), 7.08 (d, 1H, J = 5.6Hz), 6.93 (d, 1H, J = 5.6Hz), 5.40 (t, 1H, J = 5.4Hz), 4. 53-4.40(m,1H),4.20-3.95(m,6H),2.74-2.365(m,2H),2.47-2.30(m,6H),2.36-0.85(m,79H),0.70(s,3H)
[0205] Example 12 Synthesis of Compound 12
[0206] 6-((4-Hydroxybutyl)amino)hexyl 2-hexyldecanoate 1b (428 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, 4-bromobutyl cholesteryl carbonate 10a (679 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain product 12 (566 mg, light yellow oil) in a 62% yield.
[0207] MS m / z(ESI):913.0[M+1]
[0208] 1H NMR (300MHz, CDCl3): δ5.40 (t, 1H, J = 5.4Hz), 4.53-4.40 (m, 1H), 4.20-4.02 (m, 4H), 3. 67-3.61(m,2H),2.63-2.32(m,8H),2.03-1.72(m,5H),1.67-0.85(m,80H),0.70(s,3H)
[0209] Example 13 Synthesis of Compound 13
[0210] 6-((4-Hydroxybutyl)amino)hexyl 2-hexyldecanoate 1b (428 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, 4-bromobutyl cholesteryl carbonate 11a (645 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain product 13 (451 mg, light yellow oil) in a 51% yield.
[0211] MS m / z(ESI):885.1[M+1]
[0212] 1H NMR (300MHz, CDCl3): δ5.40(t,1H,J=5.4Hz),4.53-4.40(m,1H),4.29-4.21(m,2H),4.20-4.02(m,2H),3. 67-3.61(m,2H),2.85-2.78(m,2H),2.63-2.32(m,6H),2.03-1.72(m,5H),1.67-0.85(m,76H),0.70(s,3H)
[0213] Example 14 Synthesis of Compound 14
[0214] Step 1: Synthesis of 2-(hexyloxy)-1-(pentyloxy)ethyl 7-bromoheptanoate (14a)
[0215] 7-Bromoheptanoic acid (1.05 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and 2-(hexyloxy)-1-(pentyloxy)-1-ethanol (1.16 g, 5.0 mmol), DMAP (0.21 g, 2.0 mmol), and triethylamine (0.62 g, 6.0 mmol) were added and stirred to dissolve. A solution of EDC.HCl (1.10 g, 6.0 mmol) in dichloromethane was added dropwise. After completion of the addition, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3, and the mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 14a (1.08 g, light yellow oil) in a yield of 51%.
[0216] MS m / z(ESI):423.2[M+1]
[0217] Step 2: Synthesis of 2-(hexyloxy)-1-(pentyloxy)ethyl 7-((4-hydroxybutyl)amino)heptanoate (14b)
[0218] At room temperature, 2-(hexyloxy)-1-(pentyloxy)ethyl 7-bromoheptanoate 14a (1.27 g, 3 mmol) was dissolved in 20 mL of ethanol, butanolamine (4.00 g, 45 mmol) was added, and the temperature was raised to 50°C and stirred for 8 h. The reaction progress was monitored. After the starting material was completely consumed, the temperature was lowered to room temperature. The ethanol was removed at 45°C, and the crude product was dissolved in dichloromethane and washed three times with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 14b (1.05 g, light yellow oil).
[0219] MS m / z(ESI):432.4[M+1]
[0220] Step 3: Synthesis of compound 14
[0221] 2-(Hexyloxy)-1-(pentyloxy)ethyl 7-((4-hydroxybutyl)amino)heptanoate 14b (432 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, cholesteryl 8-bromooctanoate 5c (708 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to afford compound 14 (490 mg, light yellow oil) in a 52% yield.
[0222] MS m / z(ESI):942.8[M+1]
[0223] 1H NMR (300MHz, CDCl3): δ6.67 (t, 1H, J = 6.3Hz), 5.40 (t, 1H, J = 5.4Hz), 4.53-4.40 (m, 1H), 4.20-4.02 (m, 2H), 3. 67-3.61(m,2H),3.47-3.31(m,4H),2.64(t,6H,J=5.4Hz),2.37-2.25(m,6H),2.10-0.85(m,80H),0.70(s,3H)
[0224] Example 15 Synthesis of Compound 15
[0225] Step 1: Synthesis of heptadecan-9-yl 3-oxopropanoate (15a)
[0226] 3-Oxopropionic acid (0.44 g, 5.0 mmol) was dissolved in 20 mL of dichloromethane, and 9-heptadecanol (1.28 g, 5.0 mmol), DMAP (0.21 g, 2.0 mmol), and triethylamine (0.62 g, 6.0 mmol) were added and stirred to dissolve. A solution of EDC.HCl (1.10 g, 6.0 mmol) in dichloromethane was added dropwise. After completion of the addition, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3, and the mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 15a (0.78 g, light yellow oil) in a 48% yield.
[0227] MS m / z(ESI):327.3[M+1]
[0228] Step 2: Synthesis of heptadecan-9-yl 3-hydroxypropionate (15b)
[0229] Heptadecan-9-yl 3-oxopropanoate 15a (0.78 g, 2.3 mmol) was dissolved in 10 mL of n-butanol, and sodium borohydride (266 mg, 7 mmol) was added at 0°C. The mixture was stirred at room temperature for 12 h, and the reaction progress was monitored. After the starting material was completely consumed, a saturated ammonium chloride solution was added to quench the reaction. The mixture was extracted with dichloromethane, and the organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 15b (0.70 g, light yellow oil).
[0230] MS m / z(ESI):329.3[M+1]
[0231] Step 3: Synthesis of compound 15c
[0232] 3-Bromopropionic acid (306 mg, 2.0 mmol) was dissolved in 10 mL of dichloromethane. Heptadecyl-9-yl 3-hydroxypropionate 15b (658 mg, 2.0 mmol), DMAP (84 mg, 0.8 mmol), and triethylamine (248 mg, 2.4 mmol) were added and stirred to dissolve. A solution of EDC-HCl (440 mg, 2.4 mmol) in dichloromethane was added dropwise. After completion of the addition, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3. The mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to afford compound 15c (528 mg, light yellow oil) in a 57% yield.
[0233] MS m / z(ESI):463.2[M+1]
[0234] Step 4: Synthesis of compound 15d
[0235] At room temperature, compound 15c (528 mg, 1.14 mmol) was dissolved in 10 mL of ethanol, butanolamine (1.5 g, 17 mmol) was added, and the temperature was raised to 50°C and stirred for 8 h. The reaction progress was monitored. After the starting material was completely consumed, the temperature was lowered to room temperature. The ethanol was removed at 45°C, and the crude product was dissolved in dichloromethane and washed three times with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 15d (480 mg, light yellow oil).
[0236] MS m / z(ESI):472.4[M+1]
[0237] Step 5: Synthesis of compound 15e
[0238] 3-Oxopropionic acid (0.44 g, 5.0 mmol) was dissolved in 20 mL of dichloromethane, and cholesterol (1.93 g, 5.0 mmol), DMAP (0.21 g, 2.0 mmol), and triethylamine (0.62 g, 6.0 mmol) were added and stirred to dissolve. A dichloromethane solution of EDC.HCL (1.10 g, 6.0 mmol) was added dropwise, and after completion of the addition, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3, and the mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 15a (1.03 g, light yellow oil) in a yield of 45%.
[0239] MS m / z(ESI):456.4[M+1]
[0240] Step 6: Synthesis of compound 15f
[0241] Compound 15e (1.03 g, 2.2 mmol) was dissolved in 10 mL of n-butanol, and sodium borohydride (266 mg, 7 mmol) was added at 0°C. The mixture was stirred at room temperature for 12 h. The reaction progress was monitored. After the starting material was completely consumed, saturated ammonium chloride solution was added to quench the reaction. The mixture was extracted with dichloromethane, and the organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 15f (980 mg, light yellow oil).
[0242] MS m / z(ESI):459.4[M+1]
[0243] Step 7: Synthesis of compound 15g
[0244] 3-Bromopropionic acid (306 mg, 2.0 mmol) was dissolved in 10 mL of dichloromethane, and compound 15f (916 mg, 2.0 mmol), DMAP (84 mg, 0.8 mmol), and triethylamine (248 mg, 2.4 mmol) were added and stirred to dissolve. A solution of EDC-HCl (440 mg, 2.4 mmol) in dichloromethane was added dropwise. After completion of the addition, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3. The mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to afford compound 15g (629 mg, light yellow oil) in a 53% yield.
[0245] MS m / z(ESI):593.3[M+1]
[0246] Step 8: Synthesis of compound 15
[0247] Compound 15d (480 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, compound 15g (600 mg, 1.1 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 15 (384 mg, light yellow oil) in a 39% yield.
[0248] MS m / z(ESI):984.8[M+1]
[0249] 1H NMR (300MHz, CDCl3): δ5.40(t,1H,J=5.4Hz),4.53-4.30(m,6H),3.77-3.71(m,4H),3.47-3.31( m,2H),3.12-3.05(m,2H),2.68-2.60(m,8H),2.37-2.25(m,6H),2.10-0.85(m,72H),0.70(s,3H)
[0250] Example 16 Synthesis of Compound 16
[0251] Step 1: Synthesis of compound 16a
[0252] 2-Hexyldecanoic acid (1.28 g, 5.0 mmol) was dissolved in 20 mL of dichloromethane, and bis(2-hydroxyethyl) disulfide (1.54 g, 10.0 mmol), DMAP (0.21 g, 2.0 mmol), and triethylamine (0.62 g, 6.0 mmol) were added and stirred to dissolve. A solution of EDC-HCl (1.10 g, 6.0 mmol) in dichloromethane was added dropwise. After completion of the addition, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3. The mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. Compound 16a (1.00 g, light yellow oil) was obtained by column chromatography in a 51% yield.
[0253] MS m / z(ESI):393.2[M+1]
[0254] Step 2: Synthesis of compound 16b
[0255] Compound 16a (1.00 g, 2.5 mmol) was dissolved in 20 mL of dichloromethane, and triethylamine (0.76 g, 7.5 mmol) was added. The mixture was cooled to 0°C in an ice-water bath, and methylsulfonyl chloride (0.72 g, 6.2 mmol) was added. The mixture was stirred at room temperature for 16-20 hours. After the reaction was complete, the mixture was washed twice with saturated sodium bicarbonate and twice with water. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to afford compound 16b (1.00 g, a light yellow oil) in an 85% yield.
[0256] MS m / z(ESI):471.2[M+1]
[0257] Step 3: Synthesis of compound 16c
[0258] Compound 16b (1.00 g, 2.0 mmol) was dissolved in 20 mL of acetonitrile, and potassium carbonate (0.83 g, 6.0 mmol) and 4-aminobutanol (0.18 g, 2.0 mmol) were added. The mixture was stirred at room temperature for 16-20 h. After completion of the reaction, the mixture was filtered through Celite. The filtrate was added with dichloromethane and washed twice with saturated sodium bicarbonate and twice with water. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to afford compound 16c (658 mg, light yellow oil) in a 71% yield.
[0259] MS m / z(ESI):464.3[M+1]
[0260] Step 4: Synthesis of compound 16d
[0261] Cholesterol (1.93 g, 5.0 mmol) was dissolved in 20 mL of dichloromethane, and 4-dimethylaminopyridine (1.22 g, 10 mmol) was added. Then, p-nitrophenyl chloroformate (1.11 g, 5.5 mmol) was added in batches, and the reaction was stirred at room temperature for 3 h. To the reaction solution was added bis(2-hydroxyethyl) disulfide (0.86 g, 5.6 mmol), and the mixture was stirred at room temperature overnight. After TLC showed that the reaction was complete, 20 mL of dichloromethane was added to dilute the mixture, and the mixture was washed with 30 mL of saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to give product 16d (1.45 g, light yellow oil) in a yield of 51%.
[0262] MS m / z(ESI):567.4[M+1]
[0263] Step 5: Synthesis of compound 16e
[0264] Compound 16d (1.42 g, 2.5 mmol) was dissolved in 20 mL of dichloromethane, and triethylamine (0.76 g, 7.5 mmol) was added. The mixture was cooled to 0°C in an ice-water bath, and methylsulfonyl chloride (0.72 g, 6.2 mmol) was added. The mixture was stirred at room temperature for 16-20 h. After the reaction was complete, the mixture was washed twice with saturated sodium bicarbonate and twice with water. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to afford compound 16e (1.26 g, a light yellow oil) in a 78% yield.
[0265] MS m / z(ESI):645.3[M+1]
[0266] Step 6: Synthesis of compound 16
[0267] Compound 16e (1.26 g, 2.0 mmol) was dissolved in 20 mL of acetonitrile, and potassium carbonate (0.83 g, 6.0 mmol) and compound 16c (0.93 g, 2.0 mmol) were added. The mixture was stirred at room temperature for 16-20 h. After completion of the reaction, the mixture was filtered through Celite. The filtrate was added with dichloromethane and washed twice with saturated sodium bicarbonate and twice with water. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. Column chromatography afforded compound 16 (871 mg, light yellow oil) in a 43% yield.
[0268] MS m / z(ESI):1012.7[M+1]
[0269] 1H NMR (300MHz, CDCl3): δ5.40(t,1H,J=5.4Hz),4.53-4.40(m,1H),4.20-4.02(m,4H),3.67-3.61( m,2H),3.58-3.50(m,2H),2.47-2.42(m,8H),2.03-1.72(m,5H),1.67-0.85(m,74H),0.70(s,3H)
[0270] Example 17 Synthesis of Compound 17
[0271] Step 1: Synthesis of compound 17a
[0272] 4-Bromobutyric acid (0.84 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and cholesterol (1.94 g, 5.0 mmol), DMAP (0.21 g, 2.0 mmol), and triethylamine (0.62 g, 6.0 mmol) were added and stirred to dissolve. A dichloromethane solution of EDC.HCl (1.10 g, 6.0 mmol) was added dropwise. After completion of the addition, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3, and the mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 17a (1.68 g, light yellow oil) in a 63% yield.
[0273] MS m / z(ESI):535.3[M+1]
[0274] Step 2: Synthesis of compound 17
[0275] Compound 6a (463 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, compound 17a (643 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 17 (505 mg, light yellow oil) in a 55% yield.
[0276] MS m / z(ESI):918.9[M+1]
[0277] 1H NMR (300MHz, CDCl3): δ7.49 (s, 1H), 7.08 (s, 1H), 6.94 (s, 1H), 5.40 (t, 1H, J = 5.4Hz), 4. 53-4.40(m,1H),4.10-3.92(m,4H),2.48-2.25(m,11H),2.10-0.85(m,80H),0.70(s,3H)
[0278] Example 18 Synthesis of Compound 18
[0279] Step 1: Synthesis of compound 18a
[0280] 2-Hexyldecanoic acid (2.12 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and 6-bromohexylamine hydrochloride (1.09 g, 5.0 mmol), HATU (2.28 g, 6.0 mmol), and DIPEA (1.29 g, 10.0 mmol) were added and stirred at room temperature for 16 hours. The mixture was quenched with water, and dilute hydrochloric acid was added to adjust the pH to 1-3, and the layers were separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to afford compound 18a (1.40 g, light yellow oil) in a 67% yield.
[0281] MS m / z(ESI):418.3[M+1]
[0282] Step 2: Synthesis of compound 18b
[0283] At room temperature, compound 18a (1.25 g, 3 mmol) was dissolved in 20 mL of ethanol, and 1-(3-aminopropyl)imidazole (5.63 g, 45 mmol) was added. The temperature was raised to 50°C and stirred for 8 h. The reaction progress was monitored. After the starting material was completely consumed, the temperature was lowered to room temperature. The ethanol was removed at 45°C, and the crude product was dissolved in dichloromethane. The product was washed three times with saturated brine, and the organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 18b (1.42 g, light yellow oil).
[0284] MS m / z(ESI):463.4[M+1]
[0285] Step 3: Synthesis of compound 18c
[0286] 1,4-Dibromobutane (2.16 g, 10.0 mmol) was dissolved in 30 mL of n-butanol, and cholesterol (1.94 g, 5.0 mmol) and sodium hydroxide (1.20 g, 30 mmol) were added. The mixture was heated under reflux with stirring for 5 h. After completion of the reaction, dilute hydrochloric acid was added to adjust the pH to neutral. The n-butanol was removed, and the mixture was diluted with 20 mL of dichloromethane. The mixture was then washed with 30 mL of saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. Column chromatography afforded product 18c (1.25 g, light yellow oil) in a 48% yield.
[0287] MS m / z(ESI):521.3[M+1]
[0288] Step 4: Synthesis of compound 18
[0289] Compound 18b (463 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, compound 18c (625 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain product 18 (434 mg, light yellow oil) in a 48% yield.
[0290] MS m / z(ESI):903.9[M+1]
[0291] 1H NMR (300MHz, CDCl3): δ8.01(s,1H),7.49(s,1H),7.08(s,1H),6.94(s,1H),5.40(t,1H,J=5.4Hz),4.10-3 .92(m,2H),3.35(t,2H,J=5.4Hz),3.28-3.01(m,7H),2.50-2.42(m,4H),2.10-0.85(m,83H),0.70(s,3H)
[0292] Example 19 Synthesis of Compound 19
[0293] Step 1: Synthesis of compound 19a
[0294] At room temperature, 6-bromohexyl 2-hexyldecanoate 1a (1.28 g, 3 mmol) was dissolved in 20 mL of ethanol, and 1-(3-aminopropyl)-4-methylpiperazine (7.07 g, 45 mmol) was added. The temperature was raised to 50°C and stirred for 8 h. The reaction progress was monitored. After the raw materials were completely consumed, the temperature was lowered to room temperature. The ethanol was removed at 45°C, and the crude product was dissolved in dichloromethane and washed three times with saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated to give compound 19a (1.49 g, light yellow oil).
[0295] MS m / z(ESI):496.5[M+1]
[0296] Step 2: Synthesis of compound 19
[0297] Compound 19a (496 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, compound 11a (646 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 19 (543 mg, light yellow oil) in a 57% yield.
[0298] MS m / z(ESI):952.9[M+1]
[0299] 1H NMR (300MHz, CDCl3): δ5.40 (t, 1H, J = 5.4Hz), 4.53-4.40 (m, 1H), 4.20-3.95 ( m,6H),2.74-2.65(m,2H),2.47-2.40(m,6H),2.36-0.85(m,90H),0.70(s,3H)
[0300] Example 20 Synthesis of Compound 20
[0301] Step 1: Synthesis of compound 20a
[0302] 4-Bromobutanol (0.77 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and 4-dimethylaminopyridine (1.22 g, 10 mmol) was added. Then, p-nitrophenyl chloroformate (1.11 g, 5.5 mmol) was added in batches, and the reaction was stirred at room temperature for 3 h. β-Sitosterol (2.32 g, 5.6 mmol) was added to the reaction solution, and the mixture was stirred at room temperature overnight. After TLC showed that the reaction was complete, 20 mL of dichloromethane was added to dilute the mixture, and the mixture was washed with 30 mL of saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain product 20a (1.63 g, light yellow oil) in a yield of 55%.
[0303] MS m / z(ESI):593.3[M+1]
[0304] Step 2: Synthesis of compound 20
[0305] 6-((3-(1H-imidazol-1-yl)propyl)amino)hexyl 2-hexyldecanoate 6a (463 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, compound 20a (713 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 20 (547 mg, light yellow oil) in a yield of 56%.
[0306] MS m / z(ESI):976.9[M+1]
[0307] 1H NMR (300MHz, CDCl3): δ7.49 (s, 1H), 7.08 (d, 1H, J = 5.6Hz), 6.93 (d, 1H, J = 5.6Hz), 5.40 (t, 1H, J = 5 .4Hz),4.53-4.40(m,1H),4.20-3.95(m,6H),2.47-2.30(m,8H),2.36-0.85(m,87H),0.70(s,3H)
[0308] Example 21 Synthesis of Compound 21
[0309] Step 1: Synthesis of compound 21a
[0310] 6-Bromohexanoic acid (0.975 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and cholesterol (1.93 g, 5.0 mmol), DMAP (0.21 g, 2.0 mmol), and triethylamine (0.62 g, 6.0 mmol) were added and stirred to dissolve. A dichloromethane solution of EDC.HCl (1.10 g, 6.0 mmol) was added dropwise. After completion of the addition, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3, and the mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 21a (1.92 g, light yellow oil) in a 68% yield.
[0311] MS m / z(ESI):563.4[M+1]
[0312] Step 2: Synthesis of compound 21
[0313] 2-Hexyldecyl 8-((4-hydroxybutyl)amino)octanoate 5b (455 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, cholesteryl 6-bromohexanoate 21a (676 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 21 (422 mg, light yellow oil) in a 45% yield.
[0314] MS m / z(ESI):938.9[M+1]
[0315] 1H NMR (400MHz, CDCl3) δ5.27(tt,J=12.5,2.0Hz,1H),4.64(p,J=14.8Hz,1H),4.31(ddd,J=103.0,24.8,14.1Hz,2H),3.46(t,J=14 .8Hz,2H),2.78–2.63(m,6H),2.44–2.27(m,4H),2.27–1.47(m,21H),1.45–1.15(m,47H),1.15–0.96(m,4H),0.95–0.83(m,21H).
[0316] Example 22 Synthesis of Compound 24
[0317] Compound 6a (463 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, compound 18c (625 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain product 24 (470 mg, light yellow oil) in a 52% yield.
[0318] MS m / z(ESI):904.9[M+1]
[0319] 1H NMR(400MHz, CDCl3)δ7.92(s,1H),7.24–6.71(m,2H),5.27(tt,J=12.5,2.0Hz,1H),4.17–3.98(m,4H),3.57–3 .31(m,3H),2.79–2.63(m,4H),2.47–2.38(m,4H),2.37–1.77(m,7H),1.75–1.00(m,58H),0.96–0.81(m,21H).
[0320] Example 23 Synthesis of Compound 25
[0321] Step 1: Synthesis of compound 25a
[0322] 4-Bromobutyric acid (0.835 g, 5.0 mmol) was dissolved in 30 mL of dichloromethane, and cholesterol (1.93 g, 5.0 mmol), DMAP (0.21 g, 2.0 mmol), and triethylamine (0.62 g, 6.0 mmol) were added and stirred to dissolve. A dichloromethane solution of EDC-HCl (1.10 g, 6.0 mmol) was added dropwise. After completion of the addition, the mixture was stirred at room temperature for 16 hours. Water was added to quench the mixture, and dilute hydrochloric acid was added to adjust the pH to 1-3, and the mixture was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 25a (1.90 g, light yellow oil) in a yield of 71%.
[0323] MS m / z(ESI):535.4[M+1]
[0324] Step 2: Synthesis of compound 25
[0325] 2-Hexyldecyl 8-((4-hydroxybutyl)amino)octanoate 5b (455 mg, 1.0 mmol) was dissolved in tetrahydrofuran, and acetonitrile, cholesteryl 4-bromobutyrate 21a (643 mg, 1.2 mmol), potassium carbonate (550 mg, 4.0 mmol), and potassium iodide (332 mg, 2.0 mmol) were added. The mixture was stirred at 83°C for 16-20 h. The mixture was cooled to room temperature, filtered, and the residue was washed with dichloromethane. Saturated sodium bicarbonate solution was added to the filtrate, and the mixture was extracted twice with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to obtain compound 25 (373 mg, light yellow oil) in a 41% yield.
[0326] MS m / z(ESI):910.9[M+1]
[0327] 1H NMR(400MHz, CDCl3) δ5.27(tt,J=12.5,2.0Hz,1H),4.68(p,J=14.8Hz,1H),4 .31(ddd,J=103.0,24.8,13.0Hz,2H),3.46(t,J=14.8Hz,2H),2.79–2.62(m, 4H),2.43(td,J=12.2,6.0Hz,4H),2.37–2.11(m,3H),2.11–1.80(m,9H),1.7 9–1.46(m,11H),1.45–1.15(m,43H),1.14–0.98(m,4H),0.97–0.80(m,21H).
[0328] Example 24: Encapsulation of mRNA by a Three-Component LNP Composition and Characterization of LNP-mRNA
[0329] (1) Encapsulation of mRNA by LNP Composition
[0330] Taking GFP mRNA (green fluorescent protein) as an example, the construction of a steroid-cationic lipid three-component LNP-mRNA vaccine and a four-component LNP-mRNA vaccine (no cholesterol was added to the three-component; cholesterol was additionally added to the four-component) was demonstrated: the steroid-cationic lipid compound of the present invention, the auxiliary lipid (neutral phospholipid), the polyethylene glycol lipid, and the cholesterol (if present) were dissolved in an ethanol solution according to the molar ratio in Table 1 to obtain a lipid mixture, and the mRNA (GFP mRNA, green fluorescent protein) was dissolved in a pH 4.0 acetate buffer. The mRNA-LNP composition was prepared by a microfluidic device nanoparticle preparation instrument at a lipid mixture: mRNA flow rate ratio of 1:3.
[0331] (2) Characterization of LNP-mRNA
[0332] The packaged mRNA-LNPs were dialyzed and concentrated by ultrafiltration into DPBS. After sterile filtration, samples were obtained for subsequent animal experiments. Samples were collected and tested for encapsulation efficiency, average particle size, PDI, and zeta potential.
[0333] Table 1 Lipid formula molar percentage and nitrogen-phosphorus ratio of three-component LNPs formed by steroid-cationic lipid compounds
[0334] Among them, patent CN112424214A compound (1)
[0335] Patent CN112424214A compound (2)
[0336] Patent CN112424214A compound (3)
[0337] Patented US7514099B2 compound (CLinDMA):
[0338] As shown in Table 2, the results show that the composition formed by the steroid-cationic lipid of the present invention and the auxiliary phosphate, polyethylene glycol lipid and mRNA has good physical and chemical properties, such as the average particle size is between 60-100nm, the PDI is less than 0.2, and has a good polydispersity coefficient; the zeta potential is between ±10mV, with a small weak electric property; and the encapsulation efficiency is also greater than 85%. The PDI and mRNA encapsulation efficiency of the three-component lipid nanoparticle formula provided by the present invention are also better than the lipid nanoparticle formula made from the lipid compounds provided by CN112424214A and US7514099B2. At the same time, the encapsulation efficiency of the three-component lipid nanoparticles provided by the present invention is also significantly higher than that of the four-component LNP. This proves that the three-component LNP made from the steroid-cationic lipid compound provided by the present invention can achieve efficient encapsulation of mRNA.
[0339] Table 2 Characterization parameters of three-component LNP-mRNA compositions formed by steroid-cationic lipid compounds
[0340] Example 25: Cellular experiments with mRNA-LNPs compositions encoding GFP
[0341] The cell density was 6.5 × 10 5 Hep3B cells at a concentration of 1 mL / well were inoculated into a 24-well cell culture plate. After 24 hours, 500 ng of GFP mRNA-LNP (prepared in Example 24) was transfected into each well and the cell culture plate was placed in a 37°C, 5% CO2 cell culture incubator for culture. The negative control group was transfected with an equal volume of normal saline. After 24 hours, microscopy was performed to image the cells, and the results are shown in Figure 1. The results show that the three-component LNP composition formed by the steroid-cationic lipid compound of the present invention can achieve high expression of GFP-mRNA in cells, and the expression level is significantly higher than that of the control group. At the same time, the three-component LNP formula provided by the present invention is also better than the four-component LNP, which may be due to the lack of free cholesterol in the LNP formula, which is more stable.
[0342] Example 26: Animal Immunization Test of SARS-CoV-2 Antigen mRNA-LNP Composition
[0343] SARS-CoV-2 S protein antigen mRNA was used to prepare SARS-CoV-2 antigen mRNA-LNPs according to the lipid formulation in Table 1 of Example 24. Six- to eight-week-old female BALB / c mice were randomly divided into groups of 5 and immunized via intramuscular injection into the hind leg. Immunizations were administered on days 0 and 14, with a dose of 3 μg mRNA-LNP. A negative control group received an equal volume of saline. Blood was collected and serum was separated on the 14th day after immunization. The specific antibody titer against the SARS-CoV2 virus S protein antigen was detected by ELISA, and the ICS antigen-specific cellular immunity test was performed on the 28th day. The results are shown in Figures 2, 3a and 3b. The LNP1, LNP5, LNP6, LNP10 and LNP11 experimental groups can all induce good humoral immunity and cellular immunity (wherein, the left side of each group in Figure 2 is the IgG antibody titer after one immunization, and the right side is the IgG antibody titer after two immunizations; the groups in Figures 3a and 3b are TNFα+, TNFγ+, IL2+, IL4+, and IL5+ from left to right, respectively).
[0344] Example 27 Safety Evaluation of Cholesterol Cationic Compounds
[0345] CD1 mice were inoculated intramuscularly with a 30 μg dose of the SARS-CoV-2 antigen mRNA-LNP complex, while a negative control group was injected with an equal volume of saline. The safety of the three-component LNP based on Compounds 1, 6, and 11 was evaluated by monitoring the systemic inflammatory factor IL-6 in mice. As shown in Figure 4, after high-dose administration, the three-component LNP based on Compounds 1, 6, and 11 significantly reduced the expression of the systemic inflammatory factor IL-6 compared to the four-component LNP based on the marketed compound ALC-0315.
[0346] Example 28 Lyophilization Study of Cholesterol Cationic Lipid Compound Three-Component LNP
[0347] For example, the GFP-mRNA-LNP complex was dissolved in 20 mM Tris-sodium acetate (pH 7.5) buffer containing 10% sucrose by mass. 300 μL of the solution was aliquoted into 3 mL vials and freeze-dried. The freeze-drying procedure included a pre-freezing phase at -30°C for 2 hours, a desorption drying phase at 25°C for 1 hour, and a sublimation drying phase at -40°C for 2 hours and -20°C for 2 hours, with vacuum pressure maintained at ≤10 Pa throughout the process. The complex was stable at 2-8°C for 1 month. After reconstitution in sterile, enzyme-free water, the total amount of mRNA, free mRNA concentration, encapsulation efficiency, and mRNA integrity were measured.
[0348] Table 3 Changes in critical quality attributes of LNP before and after freeze-drying
[0349] The results are shown in Table 3. The stability (e.g., particle size, PDI, and encapsulation efficiency) of the three-component LNPs containing the cholesterol cationic lipid compound provided by the present invention after lyophilization was significantly higher than that of the four-component control LNPs. The particle size change of the LNPs made from the lipid compound provided by the present invention before and after lyophilization was less than 10 nm, and the encapsulation efficiency change was within 6%. In contrast, the particle size of the control LNPs increased by more than 10 nm after lyophilization, and the mRNA encapsulation efficiency also changed by more than 10%.
[0350] Example 29 Atomization Study of Cholesterol Cationic Lipid Compound Three-Component LNP
[0351] Using GFP-mRNA LNP complex, mRNA-LNP was atomized by a nebulizer and droplets were collected. The particle size, PDI and potential were measured using a nanoparticle size detector, and the content and encapsulation efficiency were measured using a Ribogreen detection kit.
[0352] Table 4 Key quality attribute parameters of LNP before and after atomization
[0353] The experimental results are shown in Table 4 and Figure 5. After atomization, the key quality attributes of LNP1, LNP4, LNP5 and LNP10 samples, such as particle size, PDI and encapsulation efficiency, changed little. After atomization, they still maintained a good particle state and the encapsulation efficiency changed by less than 10%. In contrast, the particle morphology of the control group samples was destroyed after atomization, and the mRNA encapsulation efficiency was even undetectable. The atomized samples were transfected into Hep3B cells, and 500ng mRNA-LNP / 10 5 Cells / well were added, and GFP expression levels were detected by microscopic imaging 24 hours later. The results are shown in Figure 6. The control group LNP formulation showed almost no cell expression after nebulization, while the four groups of samples LNP1, LNP4, LNP5, and LNP10 still retained good cell transfection activity after nebulization, indicating that this type of cholesterol cation three-component LNP has a more stable structure without free cholesterol.
[0354] Example 30 Expression in the lungs of mice after aerosol inhalation of LNP
[0355] Following the procedure of Example 24, Luc mRNA was encapsulated using LNP4, LNP5, and LNP10 formulations. Six hours after administration, mice were anesthetized and intraperitoneally injected with a fluorescent substrate. The mice were then sacrificed and dissected, and fluorescence imaging was performed on the heart, liver, spleen, lungs, and kidneys. The total fluorescence quantum count was calculated. The results are shown in Figures 7a and 7b (wherein, in Figure 7b, the groups are LNP4, LNP5, and LNP10, respectively, from left to right). After aerosol inhalation of Luc-mRNA-LNP, very strong fluorescence expression was detected in the lungs of mice. This indicates that the three groups of LNPs can achieve selective expression of mRNA in the mouse lungs after aerosol inhalation, further demonstrating that our designed three-component LNP based on cholesterol cationic lipid compounds can be used in aerosol inhalation therapy for mRNA.
[0356] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the above embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the above embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
[0357] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any appropriate manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.
Claims
1. A lipid nanoparticle composition for nucleic acid drug delivery, characterized in that: Contains: steroid-cationic lipid compounds, helper lipids, and polyethylene glycol lipids.
2. The lipid nanoparticle composition for nucleic acid drug delivery according to claim 1, characterized in that The molar ratio of the steroid-cationic lipid: the auxiliary lipid: the polyethylene glycol lipid is 30-80: 20-80: 0.5-20.
3. The lipid nanoparticle composition for nucleic acid drug delivery according to claim 1, characterized in that The molar ratio of the steroid-cationic lipid: the auxiliary lipid: the polyethylene glycol lipid is 30-80: 30-80: 0.5-20.
4. The lipid nanoparticle composition for nucleic acid drug delivery according to claim 1, characterized in that The polyethylene glycol lipid is selected from 2[(polyethylene glycol)-2000]N,N-tetracosylacetamide (ALC-0159), 1,2-dimyristoyl-sn-glyceromethoxypolyethylene glycol (PEG-DMG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (PEG-DSPE), PEG-disterylglycerol (PEG-DSG), PEG-dipalmitoleyl, PEG-dioleyl, PEG-distearyl, PEG-diacylglyceramide (PEG-DAG), PEG-dipalmitoylphosphatidylethanolamine (PEG-DPPE) or PEG-1,2-dimyristoyloxypropyl-3-amine (PEG-c-DMA).
5. The lipid nanoparticle composition for nucleic acid drug delivery according to claim 1, characterized in that The auxiliary lipid is selected from neutral lipids, zwitterionic lipids or anionic lipids; preferably, the auxiliary lipid is selected from 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE), 2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DOPG), oleoylphosphatidylcholine (POPC), 1-palmitoyl-2-oleoylphosphatidylethanolamine (POPE), phosphorylcholine (DOPC), Dimyristoylphosphatidylcholine (DMPC), phosphatidylcholine (PLPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DAPC), phosphatidylethanolamine (PE), egg phosphatidylcholine (EPC), dilauroylphosphatidylcholine (DLPC), dimyristoylphosphatidylcholine (DMPC), 1-myristoyl-2-palmitoylphosphatidylcholine (MPPC), 1-palmitoyl-2-myristoylphosphatidylcholine (PMPC), 1-palmitoyl-2-stearoylphosphatidylcholine (PSPC), 1,2-diacetoyl-sn-glycero-3-phosphocholine (DBPC), 1-stearoyl-2-palmitoylphosphatidylcholine (SPPC), 1,2-eicosenoyl-sn-glycero-3- Phosphocholine (DEPC), lysophosphatidylcholine, dilinoleylphosphatidylcholine distearoylphosphatidylethanolamine (DSPE), or lysophosphatidylethanolamine.
6. The lipid nanoparticle composition for nucleic acid drug delivery according to claim 1, characterized in that The composition also contains a nucleic acid drug, which is DNA or RNA, and the RNA is selected from antisense RNA, saRNA, mRNA, lncRNA, miRNA, siRNA, piRNA, gRNA, tsRNA, circRNA or self-replicating mRNA; preferably, the nucleic acid drug is mRNA; more preferably, the composition is in the form of nucleic acid drug-lipid nanoparticles.
7. The lipid nanoparticle composition for nucleic acid drug delivery according to any one of claims 1 to 6, characterized in that The steroid-cationic lipid compound has a structure shown in formula (I): wherein R1 is selected from -OR4, -NR4R5, -NR4C(=O)R5, -C(=O)OR5, -OC(=O)R5, -OC(=O)OR5, -CN, a nitrogen-containing heterocyclic group or a guanidine group; R4 and R5 are each independently selected from H, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkenyl or C 3-8 Cycloalkynyl; The G1 is selected from a chemical bond (-), C 1-9 Alkylene, C 2-9 Alkenylene, C 3-9 Alkynylidene, C 3-8 Cycloalkylene or C 3-8 Cycloalkenylene; Preferably, the number of consecutive carbon atoms in R1-G1- does not exceed 10; G2 and G3 are each independently selected from a chemical bond (-), C 1-12 Alkylene, C 2-12 Alkenylene, C 2-12 Alkynylidene, C 3- 12 Cycloalkylene, C 3-12 Cycloalkenylene, C 3-12 Cycloalkynylene or C 6-12 arylene; The L1 and L2 are each independently selected from a chemical bond (-), -O-, -S-, -O(C=O)O-, -(C=O)NR a -、-NR a (C=O)-, -O(C=O)-, -(C=O)O-, -SS-, -S(O) x -、-OS(O) x O-, -C(=O)S-, -SC(= O)-、-NR a C(=O)NRb-、-OC(=O)NR a -、-NR a C(=O)O-, -OC(=O)S-, -SC(=O)O-, -P(O)(OR a )O-、-OP(O)(OR a )O- or C 1-12 A combination of one or more of alkylene; Wherein, x is selected from 0, 1 or 2; Among them, R a , R b Each independently selected from H, C 1-12 Alkyl, C 2-12 Alkenyl or C 2-12 Alkynes; The R2 is selected from naturally occurring or non-naturally occurring steroids; The R3 is selected from naturally occurring or non-naturally occurring steroids, C 6-24 Alkyl, C 6-24 Alkenyl, C 6-24 Alkyne or C 6-24 Alkoxy.
8. The lipid nanoparticle composition for nucleic acid drug delivery according to claim 7, characterized in that The R1 is selected from -OR4, -NR4R5, pyrazolyl, imidazolyl, piperazinyl, alkylpiperazine, piperidinyl, alkylpiperidine, guanidinyl, pyrrolyl or pyrrolidinyl; the R4 and R5 are each independently selected from H, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-8 Cycloalkyl or C 3-8 Cycloalkenyl; The G1 is a chemical bond (-), C 1-9 Alkylene, C 2-9 Alkenylene, C 3-8 Cycloalkylene or C 3-8 Cycloalkenylene; Preferably, the G1 is C 1-6 Alkylene or C 2-6 alkenylene; The G2 and G3 are each independently selected from a chemical bond (-), C 1-12 Alkylene, C 2-12 Alkenylene or C 2-12 Alkyne; The L1 and L2 are each independently selected from -O(C=O)-, -(C=O)O-, -SS-, -O(C=O)O-, -NR a C(=O)O-, -(C=O)NR a -、-NR a (C=O)-, -C(=O)S-, -SC(=O)-, -OC(=O)NR a - or C 1-12 A combination of one or more of alkylene; Among them, R a H, C 1-12 Alkyl, C 2-12 Alkenyl or C 2-12 Alkyne.
9. The lipid nanoparticle composition for nucleic acid drug delivery according to claim 7, characterized in that: The R1 is selected from -OR4, -NR4R5, imidazolyl, piperazinyl or guanidinyl; The R4 and R5 are each independently selected from H or C 1-5 alkyl; The G1 is an unsubstituted C 1-6 Alkylene; The G2 and G3 are each independently selected from a chemical bond (-) or C 1-10 Alkylene; The L1 and L2 are each independently selected from -O-, -O(C=O)-, -O(C=O)O-, -(C=O)O-, -(C=O)S-, -NHC(=O)O-, -NHC(=O)-, 10. The lipid nanoparticle composition for nucleic acid drug delivery according to claim 7, characterized in that: The R2 is a sterol; Preferably, the sterol is an animal sterol, or an oxidized form or a reduced form thereof; and / or, the sterol is a plant sterol, or an oxidized form or a reduced form thereof; and / or, the sterol is a synthetic sterol, or an oxidized form or a reduced form thereof; More preferably, the sterol is selected from cholesterol, an oxidized form of cholesterol, a reduced form of cholesterol, an alkyl lithocholate, stigmasterol, stigmasterol, campesterol, ergosterol or sitosterol; More preferably, the sterol is an oxidized form of cholesterol, a reduced form of cholesterol, an alkyl lithocholate, stigmasterol, stigmasterol, campesterol, ergosterol or sitosterol; More preferably, the sterol is selected from avenasterol, β-sitosterol, brassicasterol, ergocalciferol, campesterol, cholestanol, cholesterol, coprostanol, dehydrocholesterol, streptosterol, dihydroergocalciferol, dihydrocholesterol, dihydroergosterol, melanosterol, epicholesterol, ergosterol, fucosterol, hexahydroluminosterol, hydroxycholesterol, lanosterol, luminosterol, alginosterol, sitostanol, sitosterol, stigmasterol, stigmasterol, cholic acid, glycocholic acid, taurocholic acid, deoxycholic acid or lithocholic acid; More preferably, the structural formula of the sterol is as follows: Where R is C 1-20 alkyl.
11. The lipid nanoparticle composition for nucleic acid drug delivery according to claim 7, characterized in that: The R3 is selected from: Preferably, said R3 is selected from:
12. The lipid nanoparticle composition for nucleic acid drug delivery according to claim 7, characterized in that: The compound is selected from:
13. The lipid nanoparticle composition for nucleic acid drug delivery according to any one of claims 6 to 12, characterized in that: The nitrogen-to-phosphorus ratio of the lipid nanoparticles is (1-15):1; preferably, the nitrogen-to-phosphorus ratio of the lipid nanoparticles is (1-10):
1.
14. The lipid nanoparticle composition for nucleic acid drug delivery according to any one of claims 1 to 12, characterized in that: The lipid nanoparticles have a diameter of 15 nm to 300 nm.
15. The lipid nanoparticle composition for nucleic acid drug delivery according to any one of claims 1 to 12, characterized in that: The dosage form of the composition is a liquid preparation or a lyophilized powder.
16. The method for preparing a lipid nanoparticle composition for nucleic acid drug delivery according to any one of claims 6 to 12, characterized in that: The method comprises dissolving a steroid-cationic lipid compound, an auxiliary lipid and a polyethylene glycol lipid in a solvent and then mixing the solvent with a nucleic acid drug to prepare a lipid nanoparticle composition for nucleic acid drug delivery.
17. Use of the lipid nanoparticle composition according to any one of claims 1 to 12 in preparing a biologically active substance delivery system.
18. The use according to claim 17, characterized in that The bioactive substance delivery system is an aerosol inhalation delivery system.
19. The use according to claim 18, characterized in that The aerosol inhalation delivery system is for aerosolizing the liquid preparation for administration, and / or, the aerosol inhalation delivery system is for transmucosal administration; preferably, the aerosol inhalation delivery system is for nasal inhalation administration or oral inhalation administration.
20. The use according to claim 18 or 19, characterized in that The delivery system further comprises pharmaceutically acceptable excipients. Preferably, the excipients comprise one or more combinations of sodium acetate, tromethamine, potassium dihydrogen phosphate, sodium chloride, disodium hydrogen phosphate, and sucrose.
21. The use according to claim 20, characterized in that The delivery system is a vaccine.
22. The use according to claim 21, characterized in that The vaccine is a vaccine for preventing cancer, viral infection, bacterial infection or fungal infection; preferably, the virus is selected from: norovirus, Ebola virus, coronavirus, cytomegalovirus, dengue virus, Zika virus, coxsackievirus, enterovirus, hepatitis virus, herpes simplex virus, human papillomavirus, influenza virus, Marburg virus, measles virus, polio virus, rabies virus, rotavirus or measles virus.
23. Use of the lipid nanoparticle composition according to any one of claims 1 to 12 in the preparation of a freeze-dried preparation.
Citation Information
Patent Citations
Lipid particles containing nucleic acids and related methods
CN102712935B
Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US7514099B2
Compositions and methods for enhanced delivery of agents
WO2021026358A1
Headgroup lipid compounds and compositions for intracellular delivery of therapeutic agents
WO2021055849A1
Lipid nanoparticles
WO2021250263A1
Cited By
Preparation method of lipid nanoparticles and compound thereof
CN119454649A
